

# Selim Cellek

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4720521/selim-cellek-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71  
papers

3,422  
citations

29  
h-index

58  
g-index

74  
ext. papers

3,636  
ext. citations

4.3  
avg, IF

4.69  
L-index

#	Paper	IF	Citations
71	Single-cell Transcriptomics Uncover a Novel Role of Myeloid Cells and T-lymphocytes in the Fibrotic Microenvironment in Peyronie's Disease. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	1
70	Associations Between Mobile Health Technology use and Self-rated Quality of Life: A Cross-sectional Study on Older Adults with Cognitive Impairment. <i>Gerontology and Geriatric Medicine</i> , <b>2021</b> , 7, 23337214211018924	2.3	2
69	Unwinding Fibrosis in Peyronie's Disease. <i>Journal of Sexual Medicine</i> , <b>2020</b> , 17, 838-840	1.1	1
68	Feasibility-Usability Study of a Tablet App Adapted Specifically for Persons with Cognitive Impairment-SMART4MD (Support Monitoring and Reminder Technology for Mild Dementia). <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	7
67	Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease. <i>Journal of Sexual Medicine</i> , <b>2020</b> , 17, 1848-1864	1.1	3
66	Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease. <i>Sexual Medicine Reviews</i> , <b>2019</b> , 7, 679-689	5.6	16
65	Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models. <i>European Urology</i> , <b>2019</b> , 75, 329-340	10.2	15
64	Understanding the Role of Adenosine Receptors in the Myofibroblast Transformation in Peyronie's Disease. <i>Journal of Sexual Medicine</i> , <b>2018</b> , 15, 947-957	1.1	12
63	Early Effect of Bariatric Surgery on Urogenital Function in Morbidly Obese Men. <i>Journal of Sexual Medicine</i> , <b>2017</b> , 14, 205-214	1.1	18
62	PS-08-017 Early effect of bariatric surgery on urogenital function in morbidly obese male patients. <i>Journal of Sexual Medicine</i> , <b>2016</b> , 13, S116	1.1	
61	016 Development of a High-Throughput, Cell-Based Assay for Anti-Myofibroblast Activity in Peyronie's Disease. <i>Journal of Sexual Medicine</i> , <b>2016</b> , 13, S8	1.1	
60	PS-04-004 First results from a novel cell-based assay for anti-myofibroblast activity in Peyronie's disease. <i>Journal of Sexual Medicine</i> , <b>2016</b> , 13, S89	1.1	
59	Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. <i>Nature Reviews Urology</i> , <b>2014</b> , 11, 231-41	5.5	26
58	The role of intrinsic pathway in apoptosis activation and progression in Peyronie's disease. <i>BioMed Research International</i> , <b>2014</b> , 2014, 616149	3	54
57	Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed, and Ginkgo biloba. <i>BioMed Research International</i> , <b>2014</b> , 2014, 841798	3	40
56	Solving a bottleneck in animal models of Peyronie's disease. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 639	2.8	3
55	Vasa nervorum in rat major pelvic ganglion are innervated by nitrergic nerve fibers. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 2967-74	1.1	2

54	Pathophysiology of diabetic erectile dysfunction: potential contribution of vasa nervorum and advanced glycation endproducts. <i>International Journal of Impotence Research</i> , <b>2013</b> , 25, 1-6	2.3	31
53	Common pitfalls in some of the experimental studies in erectile function and dysfunction: a consensus article. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 2770-84	1.1	10
52	Challenges in sexual medicine. <i>Nature Reviews Urology</i> , <b>2012</b> , 9, 537-42	5.5	6
51	The beta3-adrenoceptor agonist GW427353 (Solabegron) decreases excitability of human enteric neurons via release of somatostatin. <i>Gastroenterology</i> , <b>2010</b> , 138, 266-74	13.3	19
50	GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. <i>Neurogastroenterology and Motility</i> , <b>2009</b> , 21, 657-e31	4	72
49	5-hydroxyindalpine, an agonist at the putative 5-HT receptor, has no activity on human recombinant monoamine receptors but accelerates distension-induced peristalsis in mouse isolated colon. <i>Neurogastroenterology and Motility</i> , <b>2009</b> , 21, 760-e48	4	2
48	Synergy between 5-HT4 receptor activation and acetylcholinesterase inhibition in human colon and rat forestomach. <i>Neurogastroenterology and Motility</i> , <b>2008</b> , 20, 539-45	4	17
47	The investigation of putative agents, using an in vitro model, to prevent cavernosal smooth muscle dysfunction during low-flow priapism. <i>BJU International</i> , <b>2008</b> , 102, 988-92	5.6	8
46	Potentiation by cholinesterase inhibitors of cholinergic activity in rat isolated stomach and colon. <i>Pharmacological Research</i> , <b>2008</b> , 58, 297-301	10.2	14
45	Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system. <i>Gastroenterology</i> , <b>2007</b> , 133, 175-83	13.3	46
44	The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 242-50; discussion 250-2	1.1	45
43	5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. <i>Neurogastroenterology and Motility</i> , <b>2006</b> , 18, 853-61	4	57
42	Investigation of cavernosal smooth muscle dysfunction in low flow priapism using an in vitro model. <i>International Journal of Impotence Research</i> , <b>2005</b> , 17, 10-8	2.3	54
41	Let's make NO mistake!. <i>International Journal of Impotence Research</i> , <b>2005</b> , 17, 388-9	2.3	9
40	Pathophysiology of erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2005</b> , 2, 26-39	1.1	133
39	A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide. <i>Journal of Sexual Medicine</i> , <b>2005</b> , 2, 53-7	1.1	20
38	Nitrergic neurodegeneration in cerebral arteries of streptozotocin-induced diabetic rats: a new insight into diabetic stroke. <i>Diabetes</i> , <b>2005</b> , 54, 212-9	0.9	23
37	Morphological, chemical and functional analysis of catuaba preparations. <i>Planta Medica</i> , <b>2004</b> , 70, 993-1000	10.0	12

36	Point of NO return for nitrenergic nerves in diabetes: a new insight into diabetic complications. <i>Current Pharmaceutical Design</i> , <b>2004</b> , 10, 3683-95	3.3	49
35	RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 9121-6	11.5	279
34	NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. <i>International Journal of Impotence Research</i> , <b>2004</b> , 16, 195-200	2.3	20
33	Functional evidence for nitrenergic neurotransmission in a human clitoral corpus cavernosum: a case study. <i>International Journal of Impotence Research</i> , <b>2004</b> , 16, 319-24	2.3	9
32	A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats. <i>International Journal of Impotence Research</i> , <b>2004</b> , 16, 479-85	2.3	20
31	Physiology of erectile function. <i>Journal of Sexual Medicine</i> , <b>2004</b> , 1, 254-65	1.1	96
30	Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrenergic neuropathy in diabetes. <i>Diabetologia</i> , <b>2004</b> , 47, 331-9	10.3	92
29	The Rho-kinase inhibitor Y-27632 and the soluble guanylyl cyclase activator BAY41-2272 relax rabbit vaginal wall and clitoral corpus cavernosum. <i>British Journal of Pharmacology</i> , <b>2003</b> , 138, 287-90	8.6	10
28	Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. <i>Journal of Urology</i> , <b>2003</b> , 170, 2517-22	2.5	93
27	BAY41-2272, a Novel Nitric Oxide Independent Soluble Guanylate Cyclase Activator, Relaxes Human and Rabbit Corpus Cavernosum In Vitro. <i>Journal of Urology</i> , <b>2003</b> , 169, 761-766	2.5	53
26	Two phases of nitrenergic neuropathy in streptozotocin-induced diabetic rats. <i>Diabetes</i> , <b>2003</b> , 52, 2353-62	0.9	157
25	BAY41-2272, a Novel Nitric Oxide Independent Soluble Guanylate Cyclase Activator, Relaxes Human and Rabbit Corpus Cavernosum In Vitro. <i>Journal of Urology</i> , <b>2003</b> , 761-766	2.5	2
24	BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. <i>Journal of Urology</i> , <b>2003</b> , 169, 761-6	2.5	13
23	Characterization of the non-nitrenergic NANC relaxation responses in the rabbit vaginal wall. <i>British Journal of Pharmacology</i> , <b>2002</b> , 135, 546-54	8.6	38
22	Purines and pyrimidines are not involved in NANC relaxant responses in the rabbit vaginal wall. <i>British Journal of Pharmacology</i> , <b>2002</b> , 137, 513-21	8.6	7
21	Human and rabbit cavernosal smooth muscle cells express Rho-kinase. <i>International Journal of Impotence Research</i> , <b>2002</b> , 14, 1-7	2.3	78
20	Hierarchy of membrane-targeting signals of phospholipase D1 involving lipid modification of a pleckstrin homology domain. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 29152-61	5.4	21
19	A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction. <i>Expert Opinion on Investigational Drugs</i> , <b>2002</b> , 11, 1563-73	5.9	24

18	Current oral treatments for erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , <b>2002</b> , 3, 1613-29	4	8
17	Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. <i>British Journal of Pharmacology</i> , <b>2001</b> , 133, 455-8	8.6	80
16	Nitregic-noradrenergic interaction in penile erection: a new insight into erectile dysfunction. <i>Drugs of Today</i> , <b>2000</b> , 36, 135-46	2.5	27
15	Fatty acylation of phospholipase D1 on cysteine residues 240 and 241 determines localization on intracellular membranes. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 30023-7	5.4	47
14	Our second touch system: Receptive field properties of unmyelinated tactile afferents in man. <i>Acta Physiologica Scandinavica</i> , <b>1999</b> , 167, A26		12
13	Selective nitregic neurodegeneration in diabetes mellitus - a nitric oxide-dependent phenomenon. <i>British Journal of Pharmacology</i> , <b>1999</b> , 128, 1804-12	8.6	136
12	Nitregic neurotransmission mediates the non-adrenergic non-cholinergic responses in the clitoral corpus cavernosum of the rabbit. <i>British Journal of Pharmacology</i> , <b>1998</b> , 125, 1627-9	8.6	61
11	Regulation of the cardiovascular system by non-adrenergic non-cholinergic nerves. <i>Current Opinion in Nephrology and Hypertension</i> , <b>1997</b> , 6, 74-9	3.5	11
10	Nitregic control of peripheral sympathetic responses in the human corpus cavernosum: a comparison with other species. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1997</b> , 94, 8226-31	11.5	74
9	Modulation of noradrenergic responses by nitric oxide from inducible nitric oxide synthase. <i>Nitric Oxide - Biology and Chemistry</i> , <b>1997</b> , 1, 204-10	5	9
8	Nitregic modulation of cholinergic responses in the opossum lower oesophageal sphincter. <i>British Journal of Pharmacology</i> , <b>1997</b> , 122, 1043-6	8.6	11
7	Visualisation of nitric oxide released by nerve stimulation. <i>Journal of Neuroscience Research</i> , <b>1997</b> , 47, 224-32	4.4	40
6	Inhibition of nitregic relaxations by a selective inhibitor of the soluble guanylate cyclase. <i>British Journal of Pharmacology</i> , <b>1996</b> , 118, 137-40	8.6	57
5	Visualisation of nitric oxide generated by activated murine macrophages. <i>Biochemical and Biophysical Research Communications</i> , <b>1996</b> , 221, 37-41	3.4	37
4	cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1996</b> , 93, 1480-5	11.5	396
3	Characterization of nitregic neurotransmission during short- and long-term electrical stimulation of the rabbit anococcygeus muscle. <i>British Journal of Pharmacology</i> , <b>1995</b> , 115, 1149-54	8.6	29
2	Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. <i>Biochemical and Biophysical Research Communications</i> , <b>1990</b> , 173, 541-7	3.4	542
1	Cholesterol feeding attenuates endothelium-dependent relaxation response to acetylcholine in the main pulmonary artery of chickens. <i>European Journal of Pharmacology</i> , <b>1986</b> , 129, 397-400	5.3	6

